Cargando…

Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study

BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohfuji, Satoko, Ito, Kazuya, Inoue, Megumi, Ishibashi, Motoki, Kumashiro, Hiroko, Hirota, Yoshio, Kayano, Eiji, Ota, Naoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350288/
https://www.ncbi.nlm.nih.gov/pubmed/30691396
http://dx.doi.org/10.1186/s12879-019-3719-7
_version_ 1783390421572911104
author Ohfuji, Satoko
Ito, Kazuya
Inoue, Megumi
Ishibashi, Motoki
Kumashiro, Hiroko
Hirota, Yoshio
Kayano, Eiji
Ota, Naoshi
author_facet Ohfuji, Satoko
Ito, Kazuya
Inoue, Megumi
Ishibashi, Motoki
Kumashiro, Hiroko
Hirota, Yoshio
Kayano, Eiji
Ota, Naoshi
author_sort Ohfuji, Satoko
collection PubMed
description BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes zoster. METHODS: A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. RESULTS: During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes zoster were more likely to report injection-site AEs than those without a history of herpes zoster (53% vs 39%). CONCLUSIONS: The present study confirmed the safety of freeze-dried, live attenuated varicella-zoster vaccine even in patients with underlying illnesses. A history of herpes zoster might be related to development of injection-site AEs in healthy adults. TRIAL REGISTRATION: The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016.
format Online
Article
Text
id pubmed-6350288
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63502882019-02-04 Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study Ohfuji, Satoko Ito, Kazuya Inoue, Megumi Ishibashi, Motoki Kumashiro, Hiroko Hirota, Yoshio Kayano, Eiji Ota, Naoshi BMC Infect Dis Research Article BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes zoster. METHODS: A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. RESULTS: During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes zoster were more likely to report injection-site AEs than those without a history of herpes zoster (53% vs 39%). CONCLUSIONS: The present study confirmed the safety of freeze-dried, live attenuated varicella-zoster vaccine even in patients with underlying illnesses. A history of herpes zoster might be related to development of injection-site AEs in healthy adults. TRIAL REGISTRATION: The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016. BioMed Central 2019-01-28 /pmc/articles/PMC6350288/ /pubmed/30691396 http://dx.doi.org/10.1186/s12879-019-3719-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ohfuji, Satoko
Ito, Kazuya
Inoue, Megumi
Ishibashi, Motoki
Kumashiro, Hiroko
Hirota, Yoshio
Kayano, Eiji
Ota, Naoshi
Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title_full Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title_fullStr Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title_full_unstemmed Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title_short Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
title_sort safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350288/
https://www.ncbi.nlm.nih.gov/pubmed/30691396
http://dx.doi.org/10.1186/s12879-019-3719-7
work_keys_str_mv AT ohfujisatoko safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT itokazuya safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT inouemegumi safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT ishibashimotoki safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT kumashirohiroko safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT hirotayoshio safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT kayanoeiji safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy
AT otanaoshi safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy